Literature DB >> 8463241

Identification of two subunit A isoforms of the vacuolar H(+)-ATPase in human osteoclastoma.

B van Hille1, H Richener, D B Evans, J R Green, G Bilbe.   

Abstract

Subunit A is thought to be the main component of the catalytic site of the vacuolar-type H(+)-ATPase. Screening of a cDNA library made from human osteoclastoma tumor tissue revealed the presence of two isoforms of subunit A. HO68 is a cDNA of 3.1 kilobase pairs, corresponding to a mRNA of approximately 3.4 kilobases in osteoclastoma only, encoding a protein of 615 amino acids with a predicted molecular mass of 68177 Da. A second subtype, VA68, corresponding to a mRNA of approximately 4.8 kilobases was present in all tissues analyzed, and codes for a predicted protein of 617 residues and theoretical molecular mass of 68264 Da. These clones share homology with previously published subunit A sequences, and this, together with the tissue distribution of the mRNA, suggests there are ubiquitous (VA68-type) and tissue-specific (HO68-type) isoforms. HO68 shows the closest sequence homology (95% at the amino acid level) to subunit A of a proton-secreting vacuolar-type H(+)-ATPase located in the apical membrane of midgut goblet cells of tobacco hornworm larva (Manduca sexta). We propose that HO68 could correspond to an isoform of subunit A specific for a vacuolar-type H(+)-ATPase located in the osteoclast plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8463241

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Molecular aspects of osteoclast function.

Authors:  T J Hall; T J Chambers
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

2.  Resorption-cycle-dependent polarization of mRNAs for different subunits of V-ATPase in bone-resorbing osteoclasts.

Authors:  T Laitala-Leinonen; M L Howell; G E Dean; H K Väänänen
Journal:  Mol Biol Cell       Date:  1996-01       Impact factor: 4.138

3.  A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.

Authors:  L Visentin; R A Dodds; M Valente; P Misiano; J N Bradbeer; S Oneta; X Liang; M Gowen; C Farina
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 4.  The role of H(+)-ATPases in urinary acidification.

Authors:  A Constantinescu
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

5.  Heterogeneity of vacuolar H(+)-ATPase: differential expression of two human subunit B isoforms.

Authors:  B van Hille; H Richener; P Schmid; I Puettner; J R Green; G Bilbe
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

6.  Splicing factor SF1 from Drosophila and Caenorhabditis: presence of an N-terminal RS domain and requirement for viability.

Authors:  R Mazroui; A Puoti; A Krämer
Journal:  RNA       Date:  1999-12       Impact factor: 4.942

7.  Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.

Authors:  Z Zimolo; G Wesolowski; G A Rodan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.

Authors:  Kazuaki Niikura; Mikiko Takano; Masae Sawada
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

9.  Splicing factor SF3a60 is the mammalian homologue of PRP9 of S.cerevisiae: the conserved zinc finger-like motif is functionally exchangeable in vivo.

Authors:  A Krämer; P Legrain; F Mulhauser; K Gröning; R Brosi; G Bilbe
Journal:  Nucleic Acids Res       Date:  1994-12-11       Impact factor: 16.971

10.  Docetaxel enhances lysosomal function through TFEB activation.

Authors:  Jianbin Zhang; Jigang Wang; Yin Kwan Wong; Xin Sun; Yun Chen; Liming Wang; Liu Yang; Liqin Lu; Han-Ming Shen; Dongsheng Huang
Journal:  Cell Death Dis       Date:  2018-05-23       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.